WO2020032903A1

WO2020032903A1 - The use of platelet enhanced axolotl plasm in the treatment of wounds and burns

Info

Publication number: WO2020032903A1
Application number: PCT/TR2019/050667
Authority: WO
Inventors: Turan DEMIRCAN; Gürkan Öztürk; İlknur KESKİN; Mustafa KESKİN; Hasan ÇELİK
Original assignee: T.C. Istanbul Medipol Universitesi
Priority date: 2018-08-10
Filing date: 2019-08-08
Publication date: 2020-02-13

Abstract

The present invention relates to the use of platelet-enriched axolotl plasma in the treatment of wounds and burns.

Description

THE USE OF PLATELET ENHANCED AXOLOTL PLASM IN THE

TREATMENT OF WOUNDS AND BURNS

Technical Field

State of the Art

According to data from the World Health Organization, 6.6 million major burn patients and 265,000 burn-related deaths occur annually. Physical damage due to burns can cause visual and aesthetic anxiety as well as mental disorders. In addition to these, high treatment costs have led to the continuation of studies on burn treatments. Another common situation that is as commonly seen as burns is the wounds that occur as a result of accidents or war. Injuries, like burns, put great burden on individuals and societies in social, economic and health fields. In addition, mortality and morbidity are high in cases of wounds and burns .For this reason, studies to shorten the treatment period and create a faster and better recovery process are of great importance.

Currently, it is aimed to reduce the mortality and morbidity rates by minimizing wound sepsis in patients with large burns and injuries by using topical chemotherapy in burns and injuries .In such cases, many ointments are used to temporarily cover wounds. The simplest of these is bacitracin, a petroleum-based antibiotic .The most commonly used is silver sulfodiazine, which has moderate penetration to the wound. The use of silver sulfadiazine as topical antibacterial in burns and wounds dates back to the l970s.Today, silver therapeutics and silver releasing garments have been used to prevent infections in burns, open wounds and chronic ulcers.

Although silver is widely used, the concentrations required to benefit from the antibacterial effect of silver therapeutics can have a lethal effect on both keratinocytes and fibroblasts. Silver- containing products damage pathogenic bacteria and damage healthy cells for wound healing and makes no distinction between the healthy cells and pathogenic bacteria.

In addition, silver sulfadiazine or other chemotherapeutic-phytotherapeutic agents have a positive effect on wound closure, but cannot shorten the healing time and improve the quality of healing. In addition to these reasons, their major disadvantages are the lack of a significant contribution to epithelialization.

The ultimate goal of burn and wound treatment is to achieve functional healing and epithelialization of the wound as quickly as possible by minimizing functional and aesthetic losses and preventing infection. Any technical development that will allow these criteria to be fulfilled will lead to new alternatives for the treatment of wounds and burns.

In view of the state of the art, the inventors aim to develop an alternative in the treatment of wounds and burns that provides rapid wound epithelization and wound healing and also does not damage healthy cells in the wound site.

Detailed Description of the Invention

The invention relates to the use of platelet-enriched axolotl plasma in the treatment of wounds and burns.

In other words, the invention relates to platelet-enriched axolotl plasma for use in the treatment of wounds and burns.

The terms“platelet-enriched axolotl plasma" and“axolol PRP" have the same meaning and can be used interchangeably within the scope of the invention.

The term“platelet-enriched axolotl plasma" used in the context of the invention refers to platelet- rich blood plasma. Said plasma is rich in platelets and growth factors.

Because of its high growth factor, cytokine and mitogen, axolotl PRP provides more effective treatment than autologous PRP obtained from the patient in case of burns and wounds.

The inventors have found that when axolotl PRP is used in the treatment of wounds and burns, the healing of said wounds and burns accelerates healing and shortens the duration of treatment and also results in successful re-epithelialization of the wound site, which is not seen when conventional treatments are administered. In addition, aksolotl PRP modulates immune system elements that first induce healing in the intermediate and burn zone and then prevents the healing and controls inflammation reactions in order to improve wound healing.

The use of axolotl PRP results in a higher improvement in the parameters of the wound repair process compared to existing chemotherapeutic and phytotherapeutic agents as well as autologous PRP. Furthermore, the use of the invention in the treatment of wounds and burns is both advantageous and unique compared to the present methods in that it shortens the healing time, improves wound healing success, modulates the immune system and forms an ecosystem that will positively affect healing and repair.

In another aspect, the present invention relates to pharmaceutical compositions comprising Axolotl PRP.

The pharmaceutical compositions comprising the axolotl PRP according to the invention may contain at least one adjuvant in addition to the axolotl PRP.

The excipient is selected from the group comprising solvents, lubricants, glidants, fillers, density enhancers, oils, emollients, penetration enhancers, binders, disintegrants, preservatives.

Pharmaceutical compositions comprising axolotl PRP according to the invention can be in a dosage form selected from the group comprising tablet, sublingual tablet, liquid solution, suspension, paste, drop, ointment, aerosol, vaporizer, intradermal, subcutaneous, intramuscular, intraperitoneal, intravenous, cream, gel, burn dressing, skin dressing

Pharmaceutical compositions containing the axolotl PRP according to the invention can be used in the treatment of wounds and burns.

As used in the context of the invention, the term "wound" refers to acute wounds, chronic wounds, infected wounds, abrasion wounds (rupture of the outer part of the skin), tearing wounds, bruise wounds (wounds of swollen bruises resulting from the collection of dead cells and blood under the skin), concussion wounds (wounds with damage to the organs or tissues under the skin or skull, although there are no visible wounds), knife wounds, skin cuts, surgical wounds (intentionally opened wounds to the skin to perform surgical procedures), firearm wounds, thermal wounds (extreme heat, extreme cold, cold burning, sunburn wounds and the like), chemical wounds (skin wounds caused by contact with chemicals or inhalation of these substances), bites and stings (human, bee, dog, cat, bird, bat, rodent, snake, scorpion, spider and lice-like) animal wounds) electricity induced wounds.

The term "burn" as used in the invention includes first degree burns (red, non-blistering skin), second degree burns (blisters on skin and skin thickening), third degree burns (common skin thickening with white leathery appearance) and fourth degree burns (burns extending to the tendons and / or bones).

In another aspect, the present invention relates to a method for use in the preparation of Aksolotl PRP; said method comprises the steps of

a. Collection of blood from two vessels behind the axillary gills

b. Placement of the blood in receptacle whose walls are plastered with sodium citrate

c. Subjecting the receptacle to centrifuge for 10-40 minutes at ambient temperature and

d. Isolating the PRP that remains in the middle of the receptacle after centrifugation

Accordingly, in a preferred embodiment of the invention, the receptacle is centrifuged for 15-30 minutes, preferably 20 minutes.

In a preferred embodiment of the invention, receptacle whose walls are coated with sodium citrate are obtained by placing and emptying a 10% sodium citrate solution into the tube.

In a preferred embodiment of the invention the receptacle is an Eppendorf tube.

In a preferred embodiment of the invention, the centrifuge is carried out at ambient temperature, preferably at a temperature of 22-26 C.

In another aspect, the invention relates to axolotl PRP obtainable by a method comprising the steps of: a. Collection of blood from two vessels behind the axillary gills

b. Placement of the blood in a receptacle whose walls are plastered with sodium citrate

d. Isolating the PRP that remains in the middle of the receptacle after centrifugation for use in the treatment of wounds and burns.

Around these basic concepts, it is possible to develop a wide variety of applications relating to the subject matter of the invention, the invention is not limited to the examples described herein, but is essentially as set forth in the claims.

It is evident that a person skilled in the art can demonstrate the novelty disclosed in the invention using similar embodiments and / or may apply this embodiment to other fields of similar purpose as are used in the art. It is therefore evident that such embodiments will lack novelty and in particular inventive step.

Claims

1. Platelet-enriched axolotl plasma for use in the treatment of wounds and burns.

2. Use according to claim 1, wherein the wound is acute wounds, chronic wounds, infected wounds, abrasion wounds, tear wounds, bruise wounds, concussion wounds, knife wounds, skin cuts, surgical wounds, gunshot wounds, thermal wounds, chemical wounds, bites and stings, electric-induced wounds.

3. Use according to claim 1, wherein the burn may be first degree burn, second degree burn, third degree burn or fourth degree burn.

4. Pharmaceutical compositions comprising platelet-enriched Axolotl plasma for use in the treatment of wounds and burns.

5. A pharmaceutical composition according to claim 4 which comprises at least one excipient in addition to the Axolotl PRP.

6. A pharmaceutical composition according to claim 5, wherein the excipient is selected from the group comprising solvents, lubricants, glidants, fillers, density enhancers, oils, emollients, penetration enhancers, binders, disintegrants, preservatives.

7. A pharmaceutical composition according to claims 4-6 wherein the composition is in a dosage form selected from the group comprising tablet, sublingual tablet, liquid solution, suspension, paste, drop, ointment, aerosol, vaporizer, intradermal, subcutaneous, intramuscular, intraperitoneal, intravenous, cream, gel, burn dressing, skin dressing

8. A pharmaceutical composition according to claims 4-7 for use in the treatment of wounds and burns.

9. A method for the preparation of Axolotl PRP comprising the steps of;

a. Collection of blood from two vessels behind the axillary gills

b. Placement of the blood in a receptacle whose walls are plastered with sodium citrate c. Subjecting the receptacle to centrifuge for 10-40 minutes at ambient temperature and

10. The method according to claim 9, wherein the receptacle is centrifuged for 15-30 minutes.

11. A method according to claims 9-10, wherein the receptacle whose walls are coated with sodium citrate are obtained by placing and emptying a 10% sodium citrate solution into the receptacle.

12. A method according to claims 9-11, wherein the centrifuge is carried out at a temperature of 22-26 ^° C.